The timing for CV risk intervention as a critical success factor

Authors: Zuzana Zafarová;  Michal Vrablík
Authors‘ workplace: Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in: AtheroRev 2020; 5(2): 127-130

  1. Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <>.
  2. Baigent C, Blackwell L, Emberson J et al.[ Cholesterol Treatment Trialists’ (CTT) Collaboration]. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <–6736(10)61350–5>.
  3. Vrablík M, Chmelík Z, Lánská V. Kardiovaskulární rizikový profil 40letých mužů a 50letých žen v ordinacích praktických lékařů. Practicus 2015; 14(8): 15–19.
  4. Thoenes M, Bramlage P, Zhong S et al. Hypertension Control and Cardiometabolic Risk: A Regional Perspective. Cardiol Res Pract 2012; 2012: 925046. Dostupné z DOI: <>.
  5. Tůmová E, Šatný M, Vrablík M. Doporučení v praxi: jak a proč (ne)dosahují pacienti s hypertenzí a dyslipidemií cílových hodnot Výsledky průzkumu LIPIcontrol. Medicína po promoci 2018; 19(3): 269–273.
  6. Robinson JG, Williams KJ, Gidding S et al. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc 2018; 7(20): e009778. Dostupné z DOI: <>.
  7. Ference BA, Majeed F, Penumetcha R et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015; 65(15): 1552–1561. Dostupné z DOI: <>.
  8. Ference BA, Julius S, Mahajan N et al. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension 2014; 63(6): 1182–1188. Dostupné z DOI: <>.
  9. Ford I, Murray H, McCowan C et al. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation 2016; 133(11): 1073–80. Dostupné z DOI: <>.
  10. Gupta A, Mackay J, Whitehouse A et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet 2018; 392(10153): 1127–1137. Dostupné z DOI: <–6736(18)31776–8>. Erratum in Department of Error. [Lancet 2018].
  11. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25(6): 484–491. Dostupné z DOI: <>.
  12. Coleman CI, Roberts MS, Sobieraj DM et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28(5): 669–680. Dostupné z DOI: <>.
  13. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9(9 Suppl): 2–6.
  14. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147–1152. Dostupné z DOI: <>.
  15. Böhm M, Schumacher H, Laufs U et al. Effects of nonpersistance with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013; 166(2): 306–314.e7. Dostupné z DOI: <>.
  16. Shin S, Jang S, Lee TJ et al. Association between non-adherence to statin and hospitalization for cardiovascular disease and all-cause mortality in a national cohort. Int J Clin Pharmacol Ther 2014; 52(11): 948–956. <>.
  17. Yusuf S, Pais P, Afzal R et al. Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373(9672): 1341–1351. Dostupné z DOI: <–6736(09)60611–5>.
  18. Malekzadeh F, Marshall T, Pourshams A et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (’polypill’) on cardiovascular risk factors. Int J Clin Pract 2010; 64(9): 1220–1227. Dostupné z DOI: <–1241.2010.02412.x>.
  19. Rodgers A, Patel A, Berwanger O et al. [Collaborative Group PILL]. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One 2011; 6(5): e19857. Dostupné z DOI: <>. Erratum in Correction: An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. [PLoS One. 2019].
  20. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One 2012; 7: e41297. Dostupné z DOI: <>.
  21. Thom S, Poulter N, Field J et al. [UMPIRE Collaborative Group]. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310(9): 918–929. Dostupné z DOI: <>. Erratum in JAMA 2013; 310(14): 1507.
  22. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005 May 23; 165(10): 1147–1152. Dostupné z DOI: <>.
  23. Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm 2005; 62(23): 2491–2494. Dostupné z DOI: <>.
  24. Euvascor. Souhrn údajů o přípravku. Dostupné z WWW: <>.
  25. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149–1158. Dostupné z DOI: <–6736(03)12948–0>.
  26. van der Leeuw J, Oemrawsingh RM, van der Graaf Y et al. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease – results from EUROPA. Int J Cardiol. 2015; 182: 194–199. Dostupné z DOI: <>.
Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Article was published in

Athero Review

Issue 2

2020 Issue 2

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account